Eli Lilly and Co
LLY
1,240.34
-16.69
-1.33%
Eli Lilly and Co
US · LLY
#17 by market cap
Listed 1970
1,240.34
-16.69
-1.33%
Live - 5344 symbols - heartbeat 109s ago
· 2026-10-20 06:40
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 10.12, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +44.70% YoY
Margins
- Gross margin
- 83.04%
- Operating margin
- 45.56%
- Net margin
- 31.67%
Key ratios & quality
- Enterprise valuei
- 1.20T
- PEG ratioi
- 0.85
- Altman Z-Scorei
- 10.12
PEG uses trailing P/E against the 3-year net income growth rate (48.96%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 21.49B | 22.32B | 24.54B | 28.32B | 28.54B | 34.12B | 45.04B | 65.18B |
| Gross profit | 16.81B | 17.60B | 19.06B | 21.01B | 21.91B | 27.04B | 36.63B | 54.13B |
| Selling & admin expenses | 5.98B | 6.21B | 6.12B | 6.43B | 6.44B | 7.40B | 8.59B | 11.09B |
| Research & development | 5.05B | 5.60B | 5.98B | 6.93B | 7.19B | 9.31B | 10.99B | 13.34B |
| Operating profit | 5.79B | 5.79B | 6.96B | 7.64B | 8.28B | 10.33B | 17.04B | 29.70B |
| Pretax profit | 3.68B | 5.27B | 7.23B | 6.16B | 6.81B | 6.55B | 12.68B | 25.73B |
| Tax | 529.50M | 628.00M | 1.04B | 573.80M | 561.60M | 1.31B | 2.09B | 5.09B |
| Net profit | 3.23B | 8.32B | 6.19B | 5.58B | 6.24B | 5.24B | 10.59B | 20.64B |
| Basic EPS | 3 | 9 | 7 | 6 | 7 | 6 | 12 | 23 |
| Diluted EPS | 3.13 | 8.89 | 6.79 | 6.12 | 6.90 | 5.80 | 11.71 | 22.95 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 12.73B | 15.56B | 17.60B | 19.29B | 19.80B | 22.97B |
| Gross profit | 10.50B | 13.11B | 14.59B | 15.92B | 16.22B | 19.71B |
| Selling & admin expenses | 2.47B | 2.75B | 2.74B | 3.13B | 2.93B | 3.43B |
| Research & development | 2.73B | 3.34B | 3.47B | 3.80B | 3.51B | 3.82B |
| Operating profit | 5.30B | 7.02B | 8.39B | 8.99B | 9.78B | 12.46B |
| Pretax profit | 3.46B | 6.78B | 7.23B | 8.27B | 8.85B | 9.25B |
| Tax | 697.00M | 1.12B | 1.65B | 1.63B | 1.45B | 2.15B |
| Net profit | 2.76B | 5.66B | 5.58B | 6.64B | 7.40B | 7.10B |
| Basic EPS | 3 | 6 | 6 | 7 | 8 | 8 |
| Diluted EPS | 3.06 | 6.29 | 6.21 | 7.39 | 8.26 | 7.94 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 20.55B | 13.71B | 17.46B | 18.45B | 18.03B | 25.73B | 32.74B | 55.63B |
| Cash & ST investments | 7.41B | 2.44B | 3.68B | 3.91B | 2.21B | 2.93B | 3.27B | 7.27B |
| Inventory | 3.10B | 3.19B | 3.98B | 3.89B | 4.31B | 5.77B | 7.59B | 13.74B |
| Total assets | 43.91B | 39.29B | 46.63B | 48.81B | 49.49B | 64.01B | 78.72B | 112.48B |
| Total current liabilities | 11.89B | 11.78B | 12.48B | 15.05B | 17.14B | 27.29B | 28.38B | 35.23B |
| Short-term debt | 1.10B | 1.50B | 8.70M | 1.54B | 1.50B | 6.90B | 5.12B | 1.64B |
| Long-term debt | 9.20B | 13.82B | 16.59B | 15.35B | 14.74B | 18.32B | 28.53B | 40.87B |
| Total liabilities | 32,999,300,000.00 | 36,587,000,000.00 | 40,807,900,000.00 | 39,651,200,000.00 | 38,714,400,000.00 | 53,142,600,000.00 | 64,443,000,000.00 | 85,941,000,000.00 |
| Total equity | 10.91B | 2.70B | 5.83B | 9.15B | 10.78B | 10.86B | 14.27B | 26.54B |
| Retained earnings | 11.40B | 4.92B | 7.83B | 8.96B | 10.04B | 10.31B | 13.55B | 24.47B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 41.26B | 49.85B | 62.07B | 55.63B | 54.84B | 64.67B |
| Cash & ST investments | 3.22B | 3.55B | 9.91B | 7.27B | 5.28B | 8.95B |
| Inventory | 9.31B | 11.01B | 12.18B | 13.74B | 14.53B | 16.79B |
| Total assets | 89.39B | 100.92B | 114.94B | 112.48B | 116.58B | 142.28B |
| Total current liabilities | 30.07B | 39.02B | 40.14B | 35.23B | 36.63B | 47.74B |
| Short-term debt | 4.02B | 5.72B | 1.63B | 1.64B | 4.00B | 7.05B |
| Long-term debt | 34.50B | 34.18B | 40.87B | 40.87B | 39.37B | 47.86B |
| Total liabilities | 73,542,000,000.00 | 82,573,500,000.00 | 91,084,600,000.00 | 85,941,000,000.00 | 85,378,000,000.00 | 108,404,000,000.00 |
| Total equity | 15.85B | 18.35B | 23.85B | 26.54B | 31.20B | 33.88B |
| Retained earnings | 15.10B | 17.38B | 22.25B | 24.47B | 29.51B | 31.89B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 5.52B | 4.84B | 6.50B | 7.37B | 7.59B | 4.24B | 8.82B | 16.81B |
| Depreciation & amortization | 1.61B | 1.23B | 1.32B | 1.55B | 1.52B | 1.53B | 1.77B | 2.00B |
| Free cash flow | 2.51B | 3.48B | 4.47B | 5.39B | 4.60B | -3.15B | 414.00M | 5.96B |
| Dividends paid | -2.31B | -2.41B | -2.69B | -3.09B | -3.54B | -4.07B | -4.68B | -5.38B |
| Stock buybacks / issuance | -2.49B | -4.40B | -500.00M | -1.25B | -1.50B | -750.00M | -2.50B | -4.11B |
| Ending cash balance | 8.00B | 2.34B | 3.66B | 3.82B | 2.07B | 2.82B | 3.27B | 7.27B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 1.67B | 3.09B | 8.84B | 3.22B | 5.33B | 10.69B |
| Depreciation & amortization | 463.00M | 478.00M | 470.30M | 585.70M | 509.00M | 534.00M |
| Free cash flow | -1.60B | 1.28B | 6.03B | 254.20M | 2.80B | 4.48B |
| Dividends paid | -1.35B | -1.35B | -1.35B | -1.35B | -1.55B | -1.55B |
| Stock buybacks / issuance | -1.20B | -692.00M | -708.30M | -1.51B | -2.36B | -1.60B |
| Ending cash balance | 3.09B | 3.38B | 9.79B | 7.27B | 5.28B | 8.95B |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 30.18 | 133.78 | 150.18 | 76.35 | 63.63 | 48.93 | 84.84 | 101.36 |
| ROA %i | 7.27 | 20.00 | 14.42 | 11.70 | 12.71 | 9.23 | 14.84 | 21.59 |
| ROIC %i | 13.91 | 41.94 | 31.85 | 24.39 | 24.61 | 17.46 | 26.47 | 35.32 |
| 5-year avg ROE %i | 15.66 | 39.52 | 66.34 | 77.78 | 90.82 | 94.57 | 84.73 | 74.93 |
| EBIT margin %i | 16.57 | 25.39 | 30.93 | 22.94 | 25.01 | 20.63 | 29.89 | 45.56 |
| FCF / sales %i | 10.21 | 15.61 | 18.22 | 19.02 | 16.12 | -- | 0.92 | 9.15 |
| Current ratioi | 1.73 | 1.16 | 1.40 | 1.23 | 1.05 | 0.94 | 1.15 | 1.58 |
| Quick ratioi | 1.11 | 0.68 | 0.85 | 0.80 | 0.63 | 0.52 | 0.58 | 0.78 |
| Debt / assetsi | 23.45 | 38.99 | 35.59 | 34.60 | 32.81 | 39.41 | 42.74 | 37.79 |
| LT debt / equityi | 93.57 | 530.05 | 294.01 | 170.91 | 138.38 | 170.08 | 199.88 | 154.02 |
| Interest coveragei | 14.95 | 14.15 | 21.11 | 19.12 | 21.53 | 14.49 | 17.24 | -- |
| Revenue CAGR (3Y) %i | 2.50 | 1.69 | 7.10 | 9.63 | 8.54 | 11.62 | 16.73 | 31.69 |
| Net income CAGR (3Y) %i | 10.30 | 44.84 | -- | 19.98 | -9.11 | -5.42 | 23.80 | 48.96 |
| FCF CAGR (3Y) %i | 23.26 | -2.51 | 9.00 | 29.06 | 9.72 | -- | -57.49 | 9.04 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 77.73 | 86.70 | 96.82 | 101.36 | 107.65 | 102.44 |
| ROA %i | 14.49 | 15.97 | 19.33 | 21.59 | 24.55 | 21.97 |
| ROIC %i | 24.97 | 28.61 | 34.00 | 35.32 | 39.24 | 36.35 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 29.48 | 33.37 | 39.38 | 45.56 | 47.30 | 49.72 |
| FCF / sales %i | -- | -- | 10.83 | 9.15 | 14.35 | 17.02 |
| Current ratioi | 1.37 | 1.28 | 1.55 | 1.58 | 1.50 | 1.35 |
| Quick ratioi | 0.57 | 0.53 | 0.73 | 0.78 | 0.72 | 0.68 |
| Debt / assetsi | 43.09 | 39.54 | 36.98 | 37.79 | 37.20 | 38.59 |
| LT debt / equityi | 218.84 | 187.05 | 171.79 | 154.02 | 126.19 | 141.26 |
| Interest coveragei | 17.10 | 19.52 | 26.08 | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide100.00%
Quote time 2026-10-20 06:40:14 · For reference only, not investment advice and not tailored to your situation.
the GLP-1 demand curve still doesn’t look like it’s topping, manufacturing capacity is the actual bottleneck here not demand, which is a good problem to have.